Bank of New York Mellon Corp decreased its holdings in Park Hotels & Resorts Inc. (NYSE:PK – Free Report) by 2.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,359,269 shares of the financial services provider’s stock after selling 38,398 shares during the quarter. Bank of New York Mellon Corp owned 0.68% of Park Hotels & Resorts worth $14,313,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PK. Danske Bank A S bought a new stake in Park Hotels & Resorts during the third quarter worth $25,000. Fifth Third Bancorp raised its position in Park Hotels & Resorts by 68.8% in the 1st quarter. Fifth Third Bancorp now owns 2,604 shares of the financial services provider’s stock valued at $27,000 after buying an additional 1,061 shares during the last quarter. Advisory Services Network LLC bought a new position in Park Hotels & Resorts during the 3rd quarter valued at $34,000. Harbor Capital Advisors Inc. lifted its stake in Park Hotels & Resorts by 293.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 5,181 shares of the financial services provider’s stock valued at $54,000 after acquiring an additional 3,863 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Park Hotels & Resorts by 33.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,844 shares of the financial services provider’s stock worth $61,000 after acquiring an additional 1,464 shares during the last quarter. 92.69% of the stock is owned by institutional investors.
Park Hotels & Resorts Trading Down 1.7% Shares of Park Hotels & Resorts stock opened at $15.06 on Friday. The firm has a market cap of $3.03 billion, a PE ratio of -13.82, a P/E/G ratio of 2.03 and a beta of 1.33. Park Hotels & Resorts Inc. has a 1 year low of $9.84 and a 1 year high of $15.48. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.25 and a quick ratio of 1.25. The stock has a fifty day moving average price of $14.12 and a 200-day moving average price of $12.15.
Park Hotels & Resorts (NYSE:PK – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The financial services provider reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.33). The company had revenue of $622.00 million during the quarter, compared to analysts’ expectations of $609.77 million. Park Hotels & Resorts had a negative return on equity of 6.71% and a negative net margin of 8.49%.Park Hotels & Resorts’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the firm posted $0.46 earnings per share. Equities research analysts anticipate that Park Hotels & Resorts Inc. will post 1.79 EPS for the current year.
Wall Street Analyst Weigh In Several analysts have recently issued reports on PK shares. Weiss Ratings upgraded shares of Park Hotels & Resorts from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. LADENBURG THALM/SH SH raised their price target on shares of Park Hotels & Resorts from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, June 16th. Barclays boosted their price target on shares of Park Hotels & Resorts from $9.00 to $12.00 and gave the stock an “equal weight” rating in a report on Monday, June 1st. Wells Fargo & Company raised shares of Park Hotels & Resorts to a “hold” rating in a research report on Thursday, July 23rd. Finally, Morgan Stanley increased their price objective on shares of Park Hotels & Resorts from $10.50 to $11.00 and gave the company an “equal weight” rating in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $13.18.
View Our Latest Analysis on PK
Park Hotels & Resorts Profile (Free Report)
Park Hotels & Resorts Inc is a publicly traded real estate investment trust (REIT) specializing in luxury and upper-upscale hospitality properties. The company’s primary business activity involves owning and leasing premier hotels and resorts across major urban and resort destinations. Through long-term management and franchise agreements with leading hotel operators, Park generates revenue from room nights, food and beverage offerings, meetings and events, and ancillary services.
Since its spin-off from Hilton Worldwide in January 2017, Park Hotels & Resorts has assembled a diversified portfolio of more than 60 properties.
Featured Articles Five stocks we like better than Park Hotels & Resorts Microsoft Just Flipped the AI Spending Narrative Overnight Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling? Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Park Hotels & Resorts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Park Hotels & Resorts and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBank of America Corp DE Has $1.98 Billion Holdings in Abbott Laboratories $ABT
Investors in Park Hotels & Resorts Inc. (PK - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug. 21, 2026 $2.50 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Park Hotels & Resorts shares, but what is the fundamental picture for the company? Currently, Park Hotels & Resorts is a Zacks Rank #2 (Buy) in the REIT and Equity Trust - Other industry that ranks in the Top 23% of our Zacks Industry Rank. Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while none have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from 36 cents per share to 37 cents in that period.
Given the way analysts feel about Park Hotels & Resorts right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (“Park”) (NYSE: PK) today announced the reopening of the Royal Palm South Beach Miami, a Tribute Portfolio Resort (“Royal Palm”), following the completion of the iconic oceanfront resort's more than $100 million comprehensive renovation. "Our investment in the Royal Palm reflects Park's disciplined approach to capital allocation and our ability to create meaningful long-term shareholder value through high-return redevelopment projects.
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.
Park Hotels & Resorts (PK - Free Report) is a stock many investors are watching right now. PK is currently sporting a Zacks Rank #2 (Buy) and an A for Value. The stock has a Forward P/E ratio of 5.89. This compares to its industry's average Forward P/E of 17.05. Over the last 12 months, PK's Forward P/E has been as high as 7.11 and as low as 4.38, with a median of 5.77.
Investors will also notice that PK has a PEG ratio of 1.37. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. PK's PEG compares to its industry's average PEG of 1.53. PK's PEG has been as high as 6.29 and as low as 0.61, with a median of 1.28, all within the past year.
We should also highlight that PK has a P/B ratio of 0.71. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. PK's current P/B looks attractive when compared to its industry's average P/B of 1.99. Within the past 52 weeks, PK's P/B has been as high as 0.88 and as low as 0.52, with a median of 0.70.
Finally, investors should note that PK has a P/CF ratio of 6.18. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 15.83. Over the past 52 weeks, PK's P/CF has been as high as 6.25 and as low as 4.43, with a median of 5.21.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Park Hotels & Resorts is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, PK feels like a great value stock at the moment.
Even without rate cut assistance from the Federal Reserve, the real estate sector is delivering the goods for investors this year. Count the ALPS REIT Dividend Dogs ETF (RDOG) among the real estate ETFs displaying leadership traits.
RDOG, which turned 18 years old in May, focuses on the highest-yielding REITs across nine of the real estate sector’s sub-segments. Within the ALPS ETF, those segments are equally weighted, a strategy that enhances diversification while diminishing concentration risk.
RDOG is doing something right, because the ETF is up 15.1% year-to-date. Plus, it sports an enticing trailing 12-month dividend yield of 6.09%. That’s far above average among standard real estate ETFs. The ETF’s high yield and its 2026 performance may imply that it doesn’t have much of a value proposition. Upon further examination, though, there are some value plays residing in this ETF.
To RDOG for Value Real estate is a defensive sector, and there are times when those groups trade at valuations in excess of the broader market. It’s the price of admission for accessing that defensive posture. But to RDOG’s credit, some of its holdings look undervalued today. That includes dividend stalwart Realty Income (O).
“Coverage ratios are also very high, so tenants are healthy and unlikely to request rent concessions, even during downturns,” noted Morningstar analyst Kevin Brown. “The steady, stable stream of revenue has allowed Realty Income to be one of only two REITs to be members of the S&P High-Yield Dividend Aristocrats Index and have a credit rating of A- or better. This makes Realty Income one of the most dependable investments for income-oriented investors.”
Wireless tower REIT American Tower (AMT), also a member of the RDOG lineup, is another example of a REIT which Morningstar believes is offering some value today.
“We like management’s push into international markets, where growth opportunities are stronger. Many international markets, especially in Africa, are still progressing through 4G. Continued investment in new technologies, amid soaring data consumption, should drive international growth,” observed Michael Hodel of Morningstar.
Crown Castle (CCI), SBA Communications (SBAC), and Park Hotels & Resorts (PK) are other examples of RDOG components Morningstar considers undervalued.
For more news, information, and analysis, visit the ETF Building Blocks Content Hub.
Vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for RDOG for which it receives an index licensing fee. However, RDOG is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of RDOG.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in PK over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
I am upgrading Park Hotels & Resorts to a buy, driven by strong market momentum, property upgrades, and resilient top-line growth. PK demonstrates competitive positioning with a focus on upper-upscale renovations, notably achieving +27% group revenue growth at the Royal Palm South Beach. Despite volatile FFO and high leverage, PK offers a safe, elevated dividend yield (~6.8%) with solid coverage, though dividend growth is muted.
The FIFA World Cup 2026 is underway, and outside of the competition on the pitch, the competition for consumer dollars may be equally intense. Official estimates forecast U.S. accommodations and food services generating over $2.4 billion in incremental economic value from the tournament.
That number includes 21.3 million hotel room nights expected across the three host countries: the United States, Canada, and Mexico. On a granular level, FIFA and the World Trade Organization (WTO) have projected international travelers will stay an average of 12 days, attend roughly two matches each, and spend over $400 per day.
World Cup demand is one reason many hotel stocks have made a strong run this year. However, some of those stocks may present valuation concerns. A better option may be to look at full-service hotel REITs (real estate investment trusts) as direct, quantifiable beneficiaries.
Get Host Hotels & Resorts alerts:
Analysts have specifically flagged Host Hotels & Resorts (NASDAQ: HST), Park Hotels & Resorts NYSE: PK, and Ryman Hospitality Properties (NYSE: RHP) as having meaningful revenue exposure to World Cup markets. Each carries a different risk profile that may not be reflected in their respective stock charts.
Host Hotels & Resorts: The Momentum LeaderHost Hotels & Resorts has a concrete, named World Cup tie-in that the other companies on this list lack. Fairmont Mayakoba, one of its managed properties in Mexico, was officially selected to house national team delegations during the tournament. Management also specifically called out World Cup-related transient demand as a catalyst when it raised full-year 2026 guidance for comparable hotel RevPAR and EBITDAre earlier this year.
Host Hotels & Resorts Today
HST
Host Hotels & Resorts
$25.01 0.00 (0.00%)
As of 06/18/2026 04:00 PM Eastern
52-Week Range$15.11▼
$25.36Dividend Yield3.20%
P/E Ratio17.01
Price Target$23.95
HST is up 40% in 2026 and over 30% in the three months ending June 17. It’s also trading slightly above its consensus price target of $23.75. It’s fair to wonder if the biggest gains are priced in, especially with HST looking expensive by many conventional metrics.
HST has been in a steady, persistent uptrend since November, with price climbing from approximately $16 to nearly $25.
The 50-day SMA at $22.08 has been reliably ascending, and price has stayed above it cleanly. MACD is bullish with the line above the signal, but the histogram is narrowing slightly.
Of the three, HST's chart looks the most technically healthy—it's the momentum leader without a parabolic overshoot risk.
Park Hotels & Resorts: The High-Risk, High-Reward PlayPark Hotels & Resorts is a Hilton spinoff with a portfolio concentrated in urban markets, several of which are active World Cup host cities.
Park Hotels & Resorts Today
PK
Park Hotels & Resorts
$14.74 +0.03 (+0.17%)
As of 06/18/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$9.84▼
$14.95Dividend Yield6.78%
Price Target$12.95
That direct city-level exposure is the core of the bull thesis here. The stock is up roughly 30% from its May lows and is trading well above its consensus price target of $12.68.
That means the World Cup tailwind may already be largely reflected in the price.
PK also has the most dramatic chart. The stock was essentially rangebound between $10–$12 for most of the past year, then exploded higher in late May/early June, nearly a 30% move in a matter of weeks.
The 50-day SMA at $11.93 is still ascending but hasn't caught up to price at $14.64 at all, which shows how vertical that move was.
MACD is sharply positive, but the histogram is already starting to shrink, which is worth watching. That kind of parabolic move often consolidates or pulls back before continuing.
Ryman Hospitality Properties: The Indirect Play With Real ExposureRather than broad urban hotel portfolios, Ryman Hospitality Partners owns the Gaylord Hotels brand. That means massive convention and entertainment resorts in markets including Nashville, Dallas, Denver, and Washington D.C.
Ryman Hospitality Properties Today
RHP
Ryman Hospitality Properties
$125.26 +0.12 (+0.09%)
As of 06/18/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$83.82▼
$126.27Dividend Yield3.83%
P/E Ratio33.05
Price Target$122.27
Its Gaylord Texan property sits in the Dallas market, which is hosting a World Cup semifinal. Dallas is one of the highest-demand World Cup markets in the country. RHP carries a consensus Buy rating, though at $123; it is trading above its consensus price target around $122.
RHP has the cleanest uptrend of the three. Price has been steadily climbing since its April low near $95, now at $123 and well above the 50-day SMA at $109. The MACD is still bullish (line above signal), but the histogram bars are flattening, which suggests momentum is cooling after a strong run. Not a reversal signal yet, more of a "extended and catching its breath" setup.
Is It Too Late to Get in on This Trade?As noted above, each stock has made strong gains this year, and each is starting to show technical signals that momentum is slowing. But each company also shows consistency in revenue that isn’t event driven.
That fits with recent data from Accio that shows Baby Boomers and the wealthiest U.S. households are not planning to cut back on travel and entertainment spending and, in some cases, are expected to increase it, especially in luxury and experience-based segments, which fit nicely with the business model of these REITs.
For investors considering these names, the question is whether patient investors are better served waiting for a technical pullback toward the 50-day SMA on any of the three before adding exposure, rather than chasing extended moves that are already well ahead of analyst consensus.
Should You Invest $1,000 in Host Hotels & Resorts Right Now?Before you consider Host Hotels & Resorts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Host Hotels & Resorts wasn't on the list.
While Host Hotels & Resorts currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Income hunters know Invesco KBW Premium Yield Equity REIT ETF (NASDAQ:KBWY) as one of the highest-yielding equity REIT funds on the market, with a 30-day SEC yield of 8.26% and a 12-month distribution rate of 8.6%. KBWY achieves that yield by weighting small and mid-cap REITs by dividend payout rather than market cap, loading the portfolio with rent rolls Wall Street tends to overlook. The question for KBWY holders is whether those rent checks can keep funding monthly distributions of roughly $0.12 per share when the 10-year Treasury sits near 4.5% and refinancing costs remain elevated.
How the rent roll feeds the distribution KBWY tracks the KBW Nasdaq Premium Yield Equity REIT Index, a yield-weighted basket of roughly 30 small and mid-cap REITs. Because REITs must distribute at least 90% of taxable income to maintain tax pass-through status, KBWY’s monthly payout is essentially pooled rent, lease, and mortgage income from underlying landlords. The fund charges a 0.35% expense ratio and manages roughly $291 million in assets, modest enough that distribution cuts at the top can move the needle.
The holdings doing the heavy lifting The top 10 names account for about 43% of assets, so their cash flows matter disproportionately. Three concentrate the safety question:
Innovative Industrial Properties (NYSE:IIPR), the cannabis-focused triple-net REIT, sits at about 6.4% of the fund. Tenant concentration in a still-federally-illegal industry has produced rent defaults that forced AFFO guidance lower in recent quarters. The dividend has been held flat, but coverage has thinned, and a single major tenant loss would hit KBWY’s distribution within a quarter. Community Healthcare Trust (NYSE:CHCT) is about 4.6% of assets. Medical-office leases are sticky, but CHCT’s payout ratio has run above 100% of FFO, meaning the dividend is funded partly by debt and ATM equity issuance rather than operating cash flow. That is the textbook setup for an eventual trim. SL Green Realty (NYSE:SLG | SLG Price Prediction) at about 4.2% represents the Manhattan office trade. Leasing momentum has improved, and management reset the dividend lower in 2023, so the current payout looks defensible. Valuation is the bigger concern than coverage here. Hotel exposure through Park Hotels & Resorts (NYSE:PK) adds operating leverage to RevPAR trends, fine in expansion but the first lever cut in a slowdown.
What the distribution history actually says KBWY’s monthly payout has held in a tight $0.1225 to $0.1253 band across every month of 2025 and into 2026. That stability is genuine, but it follows a long reset: distributions peaked near $0.21 in 2020 before stepping down as small-cap REITs cut payouts through the rate-hiking cycle. The bleeding has stopped. The cautionary note is that KBWY has historically tracked its underlyings down quickly when they cut.
Total return puts the yield in context Price-only performance has finally turned. KBWY is up 18% year-to-date and 23% over the past year, with shares around $17. Over five years the price is up just 14%, a reminder that the distribution has carried the total-return story and NAV is sensitive to long rates. With the 10-year near the top of its 12-month range and the 2s/10s spread compressing to 0.46%, refinancing risk for highly levered small-cap REITs remains the biggest swing factor.
The verdict on KBWY’s income KBWY’s distribution looks safe in the near term and fragile over a full cycle. Monthly payouts have been stable for over a year, top holdings are mostly covering their dividends, and the fund’s yield-weighted methodology automatically rotates out of names that cut. Holders should expect the headline yield to drift lower if rates stay elevated and one or two top holdings reset payouts, but a sudden distribution collapse would require a broader small-cap REIT credit event. Investors who want REIT-adjacent income with lower volatility and meaningful dividend growth, rather than the highest current yield, typically look outside the small-cap REIT universe entirely.
TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (NYSE: PK) (“Park”) today announced that it plans to report financial results for the first quarter 2026 after the stock market closes on Thursday, April 30, 2026. Park will hold a conference call on Friday, May 1, 2026, at 11:00 a.m. Eastern Time (ET) to discuss its earnings results, current operational environment and business outlook. The conference call will be accessible by telephone and through the internet. Interested individua.
JPMorgan Chase and Co. boosted its position in shares of Park Hotels and Resorts Inc. (NYSE: PK) by 21.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,634,643 shares of the financial services provider's stock after purchasing
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
Park Hotels & Resorts Inc (NYSE:PK)Gladstone Commercial Corp (NASDAQ:GOOD)RLJ Lodging Trust (NYSE:RLJ)Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Park Hotels & Resorts (NYSE:PK – Get Free Report) and National Storage Affiliates Trust (NYSE:NSA – Get Free Report) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, dividends and analyst recommendations.
Dividends Park Hotels & Resorts pays an annual dividend of $1.00 per share and has a dividend yield of 9.0%. National Storage Affiliates Trust pays an annual dividend of $2.28 per share and has a dividend yield of 5.5%. Park Hotels & Resorts pays out -69.9% of its earnings in the form of a dividend. National Storage Affiliates Trust pays out 330.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Park Hotels & Resorts has increased its dividend for 1 consecutive years and National Storage Affiliates Trust has increased its dividend for 1 consecutive years. Park Hotels & Resorts is clearly the better dividend stock, given its higher yield and lower payout ratio.
Profitability This table compares Park Hotels & Resorts and National Storage Affiliates Trust’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Park Hotels & Resorts -11.14% -8.56% -3.30% National Storage Affiliates Trust 9.80% 5.81% 1.43% Institutional & Insider Ownership 92.7% of Park Hotels & Resorts shares are held by institutional investors. Comparatively, 100.0% of National Storage Affiliates Trust shares are held by institutional investors. 2.5% of Park Hotels & Resorts shares are held by insiders. Comparatively, 13.7% of National Storage Affiliates Trust shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation This table compares Park Hotels & Resorts and National Storage Affiliates Trust”s revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Park Hotels & Resorts $2.54 billion 0.88 -$283.00 million ($1.43) -7.81 National Storage Affiliates Trust $752.93 million 4.24 $73.78 million $0.69 60.04 National Storage Affiliates Trust has lower revenue, but higher earnings than Park Hotels & Resorts. Park Hotels & Resorts is trading at a lower price-to-earnings ratio than National Storage Affiliates Trust, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations This is a breakdown of recent ratings and target prices for Park Hotels & Resorts and National Storage Affiliates Trust, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Park Hotels & Resorts 3 8 2 0 1.92 National Storage Affiliates Trust 1 12 0 0 1.92 Park Hotels & Resorts currently has a consensus target price of $11.45, indicating a potential upside of 2.54%. National Storage Affiliates Trust has a consensus target price of $33.60, indicating a potential downside of 18.89%. Given Park Hotels & Resorts’ higher possible upside, equities research analysts clearly believe Park Hotels & Resorts is more favorable than National Storage Affiliates Trust.
Risk and Volatility Park Hotels & Resorts has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500. Comparatively, National Storage Affiliates Trust has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
Summary National Storage Affiliates Trust beats Park Hotels & Resorts on 9 of the 15 factors compared between the two stocks.
About Park Hotels & Resorts (Get Free Report)
Park Hotels & Resorts, Inc. operates as a real estate investment trust, which owns and operates hotels and resorts. It operates through the Consolidated Hotels and Unconsolidated Hotels segments. Its portfolio of hotels and resorts include the Waldorf Astoria Hotels and Resorts, Conrad Hotels & Resorts, Hilton Hotels & Resorts, DoubleTree by Hilton, Embassy Suites by Hilton, Hilton Garden Inn, Hampton by Hilton, and Curio. The company was founded by Conrad Hilton in 1919 and is headquartered in Tysons, VA.
About National Storage Affiliates Trust (Get Free Report)
National Storage Affiliates Trust is a real estate investment trust headquartered in Greenwood Village, Colorado, focused on the ownership, operation and acquisition of self storage properties predominantly located within the top 100 metropolitan statistical areas throughout the United States. As of December 31, 2023, the Company held ownership interests in and operated 1,050 self storage properties, located in 42 states and Puerto Rico with approximately 68.6 million rentable square feet, which excludes 39 self storage properties classified as held for sale to be sold to a third party. NSA is one of the largest owners and operators of self storage properties among public and private companies in the United States.
Receive News & Ratings for Park Hotels & Resorts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Park Hotels & Resorts and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEiShares Expanded Tech-Software Sector ETF Target of Unusually High Options Trading (BATS:IGV)
NEXT HEADLINE »Traders Purchase High Volume of Allogene Therapeutics Call Options (NASDAQ:ALLO)
Park Hotels & Resorts (PK) is rated 'Buy' with a conservative $17/share price target, reflecting deep undervaluation and a 9% dividend yield. PK's strategic disposal of non-core hotels and $1B renovation pipeline are expected to boost EBITDA by nearly 60% and enhance portfolio quality. Refinancing of $1.4B in 2026 maturities is underway, reducing near-term debt risk and providing $1.2B in liquidity for operational flexibility.
Cwm LLC lowered its position in shares of Park Hotels & Resorts Inc. (NYSE:PK – Free Report) by 27.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 123,709 shares of the financial services provider’s stock after selling 46,222 shares during the quarter. Cwm LLC owned about 0.06% of Park Hotels & Resorts worth $1,294,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the business. Danske Bank A S bought a new position in Park Hotels & Resorts during the third quarter worth about $25,000. Advisory Services Network LLC bought a new stake in Park Hotels & Resorts in the 3rd quarter valued at about $34,000. Clearstead Advisors LLC boosted its holdings in Park Hotels & Resorts by 326.4% in the 3rd quarter. Clearstead Advisors LLC now owns 3,198 shares of the financial services provider’s stock valued at $35,000 after purchasing an additional 2,448 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of Park Hotels & Resorts by 293.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 5,181 shares of the financial services provider’s stock worth $54,000 after purchasing an additional 3,863 shares in the last quarter. Finally, Allworth Financial LP grew its position in shares of Park Hotels & Resorts by 56.5% during the 3rd quarter. Allworth Financial LP now owns 6,136 shares of the financial services provider’s stock worth $68,000 after purchasing an additional 2,216 shares in the last quarter. Institutional investors own 92.69% of the company’s stock.
Park Hotels & Resorts Price Performance Shares of NYSE:PK opened at $11.19 on Monday. The firm has a 50 day moving average of $10.92 and a 200-day moving average of $10.89. Park Hotels & Resorts Inc. has a 12 month low of $9.57 and a 12 month high of $12.39. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 1.25. The stock has a market capitalization of $2.25 billion, a PE ratio of -7.83 and a beta of 1.39.
Park Hotels & Resorts (NYSE:PK – Get Free Report) last posted its quarterly earnings results on Thursday, February 19th. The financial services provider reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($1.50). The firm had revenue of $629.00 million for the quarter, compared to analyst estimates of $621.79 million. Park Hotels & Resorts had a negative return on equity of 8.56% and a negative net margin of 11.14%.The business’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.39 EPS. Park Hotels & Resorts has set its FY 2026 guidance at 1.730-1.89 EPS. On average, equities research analysts predict that Park Hotels & Resorts Inc. will post 1.76 EPS for the current fiscal year.
Park Hotels & Resorts Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st were issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 8.9%. The ex-dividend date of this dividend was Tuesday, March 31st. Park Hotels & Resorts’s dividend payout ratio (DPR) is currently -69.93%.
Wall Street Analyst Weigh In A number of equities research analysts have recently weighed in on the stock. Truist Financial lifted their price target on shares of Park Hotels & Resorts from $11.00 to $12.00 and gave the company a “hold” rating in a research report on Thursday, March 26th. Wall Street Zen raised Park Hotels & Resorts from a “sell” rating to a “hold” rating in a research report on Sunday, March 1st. Barclays restated an “equal weight” rating and set a $9.00 price objective (down from $13.00) on shares of Park Hotels & Resorts in a research note on Tuesday, April 7th. Cantor Fitzgerald lifted their price objective on Park Hotels & Resorts from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. upped their target price on Park Hotels & Resorts from $10.00 to $11.00 and gave the company an “underweight” rating in a research report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $11.45.
Check Out Our Latest Research Report on PK
Park Hotels & Resorts Profile (Free Report)
Park Hotels & Resorts Inc is a publicly traded real estate investment trust (REIT) specializing in luxury and upper-upscale hospitality properties. The company’s primary business activity involves owning and leasing premier hotels and resorts across major urban and resort destinations. Through long-term management and franchise agreements with leading hotel operators, Park generates revenue from room nights, food and beverage offerings, meetings and events, and ancillary services.
Since its spin-off from Hilton Worldwide in January 2017, Park Hotels & Resorts has assembled a diversified portfolio of more than 60 properties.
Further Reading Five stocks we like better than Park Hotels & Resorts Want to see what other hedge funds are holding PK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Park Hotels & Resorts Inc. (NYSE:PK – Free Report).
Receive News & Ratings for Park Hotels & Resorts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Park Hotels & Resorts and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECheniere Energy, Inc. $LNG Shares Sold by Cwm LLC
NEXT HEADLINE »Evergreen Capital Management LLC Invests $456,000 in Teck Resources Ltd $TECK
Key Takeaways CLDT heads into Q1 with a 3.23% ESP, 5.06% revenue growth and a projected 14.29% FFO gain.HST targets Q1 growth as a stronger group and leisure demand support RevPAR and margins.PK prepares to report as premium pricing, asset sales, and leisure demand drive growth. With the first-quarter earnings season underway, early reports are grabbing investors' attention for reporting solid profits. Rather than chasing stocks that have already surged on solid reports, consider targeting companies positioned for positive surprises. Earnings beats often act as catalysts, lifting confidence and driving shares higher.
This is likely to be reflected in the earnings releases of Chatham Lodging Trust REIT (CLDT - Free Report) , Host Hotels & Resorts (HST - Free Report) , Park Hotels & Resorts (PK - Free Report) and DiamondRock Hospitality (DRH - Free Report) .
REITs play a vital role in both the physical and digital sides of the economy and often show resilience even in challenging markets. Taking a closer look at the sector’s fundamentals can help investors spot areas of steady performance and long-term growth potential. Here’s a look at where the industry’s strengths lie and how it could still present value amid broader market uncertainty.
Particularly, the hotel industry demonstrated resilient growth in the first quarter of 2026. According to CBRE data, overall hotel occupancy increased 0.8% year over year as demand growth of 2% surpassed the 0.6% rise in supply in the quarter. Revenue per available room (RevPAR) climbed 3.8% year over year, bolstered by a 2.2% increase in the average daily rate (ADR), with real (inflation-adjusted) RevPAR growth settling at 1% after accounting for a 2.7% inflation rate.
Performance varied significantly across regions in the quarter, with San Francisco experiencing a notable 31% surge in RevPAR fueled by AI-sector corporate travel, while New Orleans saw a 20% decline in RevPAR following last year’s Super Bowl surge in demand. Despite these regional shifts, the sector faces upward pressure from rising labor costs, as hotel wages grew by 4.2% in the first quarter of 2026, outpacing the broader 3.6% national wage growth.
The Zacks MethodologyPicking the right stock could be difficult unless one knows the proper method. To make the task simple, we rely on the Zacks methodology, combining a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) and a positive Earnings ESP.
Our proprietary methodology, Earnings ESP, shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate. Research shows that for stocks with this combination of the Zacks Rank and ESP, chances of a positive earnings surprise are as high as 70%.
Here are four Hotel REITs that have the right combination of elements to deliver positive surprises this earnings season.
Chatham Lodging Trust currently has an Earnings ESP of +3.23% and sports a Zacks Rank of #1. Over the trailing four quarters, the company’s funds from operations (FFO) per share surpassed the Zacks Consensus Estimate on three occasions and missed on the other, the average beat being 11.21%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Chatham Lodging is expected to have benefited from its scaled portfolio of upscale extended stay and premium branded select service hotels in key markets. The company’s track record of outperforming the industry suggests that the first quarter could see stabilization or slight upward momentum in occupancies and rates. A focus on hotel asset quality is likely to have helped the revenues trend positively. The recent 11% dividend hike reinforces income appeal and management’s optimism about sustainable earnings power. Also, the hotel REIT is expected to continue enjoying balance sheet strength.
Chatham Lodging is slated to report first-quarter 2026 results on May 7, before market open.
The Zacks Consensus Estimate for quarterly revenues is presently pegged at $65.17 million, which indicates a decrease of 5.06% year over year. The consensus mark for the quarterly FFO per share is pegged at 16 cents, which indicates 14.29% year-over-year growth.
Host Hotels & Resorts currently has an Earnings ESP of +2.41% and carries a Zacks Rank of #3. Over the trailing four quarters, the company’s adjusted funds from operations (AFFO) per share outpaced the Zacks Consensus Estimate on all occasions, with the average beat being 10.65%.
Host Hotels is likely to have gained by its portfolio of luxury and upper-scale hotels across the top U.S. Markets and the Sunbelt region. The improvement in group and transient demand, including leisure and resort, is expected to have aided hotel RevPAR growth in the to-be-reported quarter. The company’s strategic capital allocations are likely to have improved portfolio quality and strengthened its position in key U.S. markets, where it has a greater scale and competitive advantage. This is likely to have given it an edge and driven margin expansion. However, high interest expenses are likely to have been a spoilsport for HST during the to-be-reported quarter.
Host Hotels is scheduled to release its first-quarter earnings on May. 6, after market close.
The Zacks Consensus Estimate for quarterly revenues is pegged at $1.63 billion, which suggests a 2.02% increase from the year-ago quarter’s reported figure. While the consensus mark for first-quarter 2026 AFFO per share is pegged at 62 cents, implying a 3.13% decrease year over year.
Park Hotels & Resorts has an Earnings ESP of +2.27% and carries a Zacks Rank #3 at present. Over the trailing four quarters, PK’s FFO per share surpassed the Zacks Consensus Estimate thrice and missed in the remaining period, with the average beat being 5.12%.
Park Hotels is expected to have gained from its diverse portfolio of hotels and resorts. The company is likely to report RevPAR growth, driven by sustained leisure demand and stabilizing group bookings as supply pressures ease in key markets. Looking ahead, the company stands to capitalize on premium pricing power and operational efficiencies. As asset sales advance smoothly, PK is strengthening its balance sheet, unlocking capital for strategic reinvestments, and positioning for accelerated, long-term growth.
Park Hotels is scheduled to report its quarterly figures on April 30, after market close.
The Zacks Consensus Estimate for first-quarter total revenues is pegged at $614.63 million, indicating a 2.44% decrease year over year. The consensus mark for the quarterly FFO per share stands at 40 cents, suggesting a 13.04% decrease year over year.
DiamondRock Hospitality currently has an Earnings ESP of +1.78% and carries a Zacks Rank of #3. Over the trailing four quarters, the company’s FFO per share surpassed the Zacks Consensus Estimate on all occasions, the average beat being 11.58%.
DiamondRock Hospitality is positioned to benefit from its geographically diversified portfolio of premium hotels concentrated in leisure destinations and top gateway markets. A cleaner balance sheet following 2025 refinancings and stronger group and resort demand trends, including higher pricing in premium leisure markets, supports the to-be-reported quarter results. However, management explicitly guided first-quarter 2026 RevPAR to be "essentially flat" year-over-year, describing it as the toughest comparison of the year.
DiamondRock Hospitality is slated to report first-quarter 2026 results on April 30, after market close.
The Zacks Consensus Estimate for quarterly revenues is presently pegged at $255.94 million, which indicates an increase of 0.43% year over year. The consensus mark for the quarterly FFO per share is pegged at 19 cents, which remains unchanged year over year.
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (“Park” or the “Company”) (NYSE: PK) today announced results for the first quarter ended March 31, 2026 and provided an operational update and an update on its Non-Core hotel disposition initiative. First Quarter Highlights Include: Comparable RevPAR was $191.05, an increase of 2.2% compared to the same period in 2025, or a 5.5% increase when excluding the Royal Palm South Beach Miami, a Tribute Portfolio Resort (“Royal Palm”), which.
Park Hotels & Resorts (PK - Free Report) came out with quarterly funds from operations (FFO) of $0.45 per share, beating the Zacks Consensus Estimate of $0.4 per share. This compares to FFO of $0.46 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an FFO surprise of +11.94%. A quarter ago, it was expected that this company would post FFO of $0.48 per share when it actually produced FFO of $0.51, delivering a surprise of +6.25%.
Over the last four quarters, the company has surpassed consensus FFO estimates three times.
Park Hotels & Resorts, which belongs to the Zacks REIT and Equity Trust - Other industry, posted revenues of $622 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.58%. This compares to year-ago revenues of $630 million. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.
Park Hotels & Resorts shares have added about 8.4% since the beginning of the year versus the S&P 500's gain of 4.2%.
What's Next for Park Hotels & Resorts?While Park Hotels & Resorts has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Park Hotels & Resorts was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.62 on $670.91 million in revenues for the coming quarter and $1.86 on $2.53 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Other is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Vornado (VNO - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 4.
This real estate investment trust is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of -17.5%. The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level.
Vornado's revenues are expected to be $443.27 million, down 4% from the year-ago quarter.
For the quarter ended March 2026, Park Hotels & Resorts (PK - Free Report) reported revenue of $622 million, down 1.3% over the same period last year. EPS came in at $0.45, compared to -$0.29 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $618.44 million, representing a surprise of +0.58%. The company delivered an EPS surprise of +11.94%, with the consensus EPS estimate being $0.40.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Park Hotels & Resorts performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Comparable RevPAR Growth: 2.2% compared to the 0.9% average estimate based on three analysts.Total Number of rooms: 20,467 versus 21,404 estimated by two analysts on average.Comparable RevPAR: $191.05 million versus $183.16 million estimated by two analysts on average.Revenues- Rooms: $356 million compared to the $348.41 million average estimate based on three analysts. The reported number represents a change of -1.9% year over year.Revenues- Ancillary hotel: $60 million compared to the $62.63 million average estimate based on two analysts. The reported number represents a change of -4.8% year over year.Revenues- Food and beverage: $182 million compared to the $181.69 million average estimate based on two analysts. The reported number represents a change of 0% year over year.Revenues- Other: $24 million versus the two-analyst average estimate of $22.11 million. The reported number represents a year-over-year change of +9.1%.Earnings per share - Diluted: $0.05 compared to the $0.04 average estimate based on three analysts.View all Key Company Metrics for Park Hotels & Resorts here>>>
Shares of Park Hotels & Resorts have returned +9.3% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
TYSONS, Va.--(BUSINESS WIRE)---- $PK--Park Hotels & Resorts Inc. (NYSE: PK) (“Park”) today announced that it plans to report financial results for the second quarter 2026 after the stock market closes on Thursday, August 6, 2026. Park will hold a conference call on Friday, August 7, 2026, at 11:00 a.m. Eastern Time (ET) to discuss its earnings results, current operational environment and business outlook. The conference call will be accessible by telephone and through the internet. Interested indiv.
On June 04, 2026, Park Hotels & Resorts Inc PK shares rose 3.9% to $14.04, reflecting a strong performance amidst a volatile market. The stock has traded within a 52-week range of $9.84 to $14.11, showcasing significant growth over the past year.
GF Value™ verdict: Current price of $14.04 is 2.6% overvalued compared to the GF Value™ of $13.69.GF Score™ of 78/100 indicates that PK is above average in terms of its investment quality.Notable signal: No insider transactions have been recorded in the last 3 months. Is PK Overvalued or Undervalued? The current price of Park Hotels & Resorts Inc PK at $14.04 is slightly above the GF Value™ estimate of $13.69, indicating that the stock is approximately 2.6% overvalued. This valuation suggests that there may be limited margin for safety for new investors looking to enter the stock at this level. The GF Valuation label classifies the stock as fairly valued, which implies that while the company may have solid fundamentals, the current market price does not present a significant opportunity for upside risk.
GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates. Being overvalued entails risks, particularly if market sentiment shifts or if the company’s operational performance does not meet investor expectations in the near future.
How Does PK's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 38.4x 17.4x Park Hotels & Resorts Inc PK is currently trading at a forward P/E of 38.4x, which is significantly higher than its 5-year median P/E of 17.4x. This indicates that the stock is trading above its historical valuation metrics, which aligns with the GF Value™ verdict of being overvalued. The high forward P/E suggests that investors are paying a premium for expected future growth, but it also raises concerns about the sustainability of the price increase if the growth outlook does not materialize.
What Does PK's GF Score™ Tell Us? Metric Rating GF Score™ 78/100 Financial Strength 4/10 Profitability 7/10 Growth 5/10 Valuation 9/10 Momentum 8/10 The GF Score™ of 78/100 indicates that Park Hotels & Resorts Inc PK has above-average investment quality. The strongest area is its Valuation rank of 9/10, suggesting that the stock has favorable valuation metrics relative to its peers. However, the Financial Strength score of 4/10 signals potential concerns regarding the company's financial stability. Profitability and Momentum ranks are moderately strong at 7/10 and 8/10, respectively, indicating that the company is performing well in terms of profits and stock performance momentum.
What Are Insiders Doing with PK Stock? There have been no insider transactions in the last 3 months for Park Hotels & Resorts Inc PK . This lack of activity may suggest that insiders are not currently taking positions that could indicate a strong belief in the stock's future performance, either positively or negatively. Absence of insider buying could imply that insiders are not confident in the stock's current valuation or future prospects.
What This Means for Investors Based on the GF Value™ assessment, Park Hotels & Resorts Inc PK is currently overvalued at $14.04 compared to the estimated fair value of $13.69. Investors may want to consider the risks associated with entering a position at this price level, especially given the high forward P/E ratio and the absence of insider activity in recent months.
For the complete analysis, visit the Park Hotels & Resorts Inc PK stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is PK's GF Score™?
The GF Score™ for Park Hotels & Resorts Inc PK is 78/100, indicating that it has an above-average investment quality based on various fundamental metrics.
Is PK overvalued or undervalued?
PK is currently overvalued, with a GF Value™ estimate of $13.69 compared to its current price of $14.04.
What is PK's P/E ratio?
The current forward P/E for Park Hotels & Resorts Inc PK is 38.4x, which is significantly higher than its historical 5-year median P/E of 17.4x, indicating that the stock is trading above its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
The benefit of the Federal Reserve lowering interest rates may not happen until late this year, if at all. Even so, listed real estate investment trusts (REITs) are delivering for investors.
Read more: Green Shoots Emerging in the Real Estate Sector
For example, the largest real estate ETF is higher by 8.60% year-to-date, but the ALPS REIT Dividend Dogs ETF (RDOG) far exceeds that. RDOG is up 14.38% since the start of 2026, outpacing its larger rival and the broader market in the process. The ETF, which tracks the S-Network REIT Dividend Dogs Index, turned 18 years old last month. It’s outperforming with a trailing 12-month yield of 6.14% — above-average in a category known for its potent income streams.
Of course, RDOG’s bullishness is aided by holding the right REITs, including Park Hotels & Resorts (PK), the ETF’s fourth-largest holding and a stock that some experts view as offering value.
“Park Hotels & Resorts holds the first spot as the least expensive company on our list of the best REITs to buy, trading 34% below our fair value estimate of $19.50 per share,” noted Morningstar’s Tori Brovet. “Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. It also offers the highest REIT forward dividend yield on our list at 7.75%.”
Not a Gamble, But… RDOG embodies the defensive spirit of the real estate sector. Neither the sector nor the ETF are “gambles” in the true sense of that word. However, the ETF could benefit from goings on in the casino world, because Vici Properties (VICI) and Gaming and Leisure Properties (GLPI) — the two largest owners of casino real estate — are RDOG member firms.
Amid a spate of large-scale consolidation activity in that space, including Barry Diller offering $18 billion for MGM Resorts (MGM) and Tilman Fertitta bidding $17.6 billion for Caesars Entertainment (CZR), analysts see avenues for the two RDOG holdings to benefit.
That would likely come from the REITs diversifying tenant rosters or adding properties to their portfolios. At the same time, large acquired companies could potentially shed some assets.
“Another potential consequence of the CZR deal, in our view, is potential pickup in M&A interest from proven (mid-tier) operators that could already be in the process of arranging financing for some properties believed to be under operated. VICI also sees intriguing opportunity with the mix of brands under the CZR’s umbrella, that could extract value if prioritized,” observed Truist analyst Barry Jonas.
For more news, information, and analysis, visit the ETF Building Blocks Content Hub.
Vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for RDOG for which it receives an index licensing fee. However, RDOG is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi has no obligation or liability in connection with the issuance, administration, marketing, or trading of RDOG.
Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with previously reported single-ascending dose (SAD) and crossover data, supporting its planned development in patients with generalized anxiety disorder (GAD).
The MAD data showed that seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses that reduce liver exposure and are projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited agomelatine’s clinical use. GlyphAgo AUC0-24 and Cmax increased dose-dependently over the range of doses studied, and agomelatine exposures following GlyphAgo administration in the MAD portion were consistent with data from the SAD and crossover portions of the trial. There was no unmodified agomelatine arm in the MAD portion.
Across all dose levels evaluated, GlyphAgo was well tolerated, with no serious or severe adverse events, no liver-related adverse events, and no clinically significant changes in liver-related laboratory parameters observed, further supporting observations from the SAD and crossover cohorts.
“We are enthusiastic about the data from our Phase 1 program for GlyphAgo, where we’ve now observed consistent safety, tolerability, and PK across all cohorts,” said Daphne Zohar, Co-Founder and Chief Executive Officer of Seaport Therapeutics. “We believe these results substantially derisk our future clinical development approach and strengthen the differentiated profile of GlyphAgo. The complete Phase 1 data package further validates our Glyph platform and supports the advancement of GlyphAgo into two parallel Phase 2 trials as we work to bring a new treatment option to patients with generalized anxiety disorder who have not had a new medicine approved in almost 20 years.”
The Phase 1 proof-of-concept trial, which included 174 participants, was conducted in multiple parts to evaluate the safety, tolerability, and PK of GlyphAgo and to compare the PK of GlyphAgo to agomelatine alone. The trial included SAD and MAD cohorts, as well as a crossover portion (including both food-effect and within-participant comparison between GlyphAgo and agomelatine), using both open-label and placebo-controlled designs.
In the previously reported results from the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared with orally administered unmodified agomelatine. GlyphAgo also showed significantly lower (10-fold) PK variability compared to unmodified agomelatine. The crossover portion included participants who were taking estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In contrast, GlyphAgo exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo to bypass first-pass liver metabolism. GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives.
Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026.This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028. Seaport also expects to initiate a Phase 2b trial of GlyphAgo in the first half of 2027. This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD. Topline data from this trial are expected by the end of 2028. Seaport plans to present additional analyses from the Phase 1 trial at future upcoming scientific meetings.
About GlyphAgoTM (SPT-320 or Glyph Agomelatine)
GlyphAgo is a novel, “Glyphed” oral prodrug of agomelatine, a clinically validated anti-anxiety and antidepressant that is approved for the treatment of GAD in Australia and Major Depressive Disorder in Australia and the European Union. Using Seaport’s proprietary GlyphTM platform, GlyphAgo is designed to enhance lymphatic absorption and avoid first-pass liver metabolism, thereby enhancing oral bioavailability and reducing side effects. By leveraging an alternative absorption pathway via the intestinal lymphatic system used by dietary fats, GlyphAgo is designed to increase systemic exposure of agomelatine, enabling exposure levels of agomelatine that are effective in GAD but at a lower dose that reduces liver exposure and reduces or eliminates the need for liver function testing. Based on the data generated to date, Seaport believes GlyphAgo has the potential to become a leading treatment for GAD.
About Seaport Therapeutics
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding our product candidates, preclinical and clinical development activities and timelines, including projected data announcements, and our expectations for future operations and financial performance. These statements include, among other things, Seaport Therapeutics’ expectations regarding the concurrent Phase 2 trials of GlyphAgo (SPT-320), including the expected trial design and the timing of topline data.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Seaport Therapeutics’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; Seaport Therapeutics’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Seaport Therapeutics’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Seaport Therapeutics’ intellectual property protections; and risks related to the competitive landscape for Seaport Therapeutics’ product candidates; as well as other risks described in “Risk Factors,” in Seaport Therapeutics’ Registration Statement on Form S-1 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. Seaport Therapeutics expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Seaport uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260608037260/en/
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with previously reported single-ascending dose (SAD) and crossover data, supporting its planned advancement of GlyphAgo into two parallel Phase 2 trials in patients with generalized anxiety disorder (GAD).
Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026. This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028.
Seaport also expects to initiate a Phase 2b trial of GlyphAgo in the first half of 2027. This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD. Topline data from this trial are expected by the end of 2028.
The GlyphAgo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company’s strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech’s Founded Entity, Seaport Therapeutics.
The full text of the announcement from Seaport is as follows:
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Repeat dosing of GlyphAgo confirms favorable safety, tolerability, and pharmacokinetics observed across the Phase 1 program, with no liver-related adverse events observed
New data demonstrate seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing
Results support dose selection and planned advancement into two parallel Phase 2 trials in patients with generalized anxiety disorder
BOSTON, June 8, 2026 -- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with previously reported single-ascending dose (SAD) and crossover data, supporting its planned development in patients with generalized anxiety disorder (GAD).
The MAD data showed that seven-day dosing of GlyphAgo achieved therapeutic exposures of agomelatine at doses that reduce liver exposure and are projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing that has previously limited agomelatine’s clinical use. GlyphAgo AUC0-24 and Cmax increased dose-dependently over the range of doses studied, and agomelatine exposures following GlyphAgo administration in the MAD portion were consistent with data from the SAD and crossover portions of the trial. There was no unmodified agomelatine arm in the MAD portion.
Across all dose levels evaluated, GlyphAgo was well tolerated, with no serious or severe adverse events, no liver-related adverse events, and no clinically significant changes in liver-related laboratory parameters observed, further supporting observations from the SAD and crossover cohorts.
“We are enthusiastic about the data from our Phase 1 program for GlyphAgo, where we’ve now observed consistent safety, tolerability, and PK across all cohorts,” said Daphne Zohar, Co-Founder and Chief Executive Officer of Seaport Therapeutics. “We believe these results substantially derisk our future clinical development approach and strengthen the differentiated profile of GlyphAgo. The complete Phase 1 data package further validates our Glyph platform and supports the advancement of GlyphAgo into two parallel Phase 2 trials as we work to bring a new treatment option to patients with generalized anxiety disorder who have not had a new medicine approved in almost 20 years.”
The Phase 1 proof-of-concept trial, which included 174 participants, was conducted in multiple parts to evaluate the safety, tolerability, and PK of GlyphAgo and to compare the PK of GlyphAgo to agomelatine alone. The trial included SAD and MAD cohorts, as well as a crossover portion (including both food-effect and within-participant comparison between GlyphAgo and agomelatine), using both open-label and placebo-controlled designs.
In the previously reported results from the head-to-head crossover portion of the trial, GlyphAgo demonstrated a 6.8-fold increase in bioavailability of agomelatine compared with orally administered unmodified agomelatine. GlyphAgo also showed significantly lower (10-fold) PK variability compared to unmodified agomelatine. The crossover portion included participants who were taking estrogen-containing oral contraceptives that are known to increase agomelatine exposure due to liver drug-drug interaction. In contrast, GlyphAgo exposure was unaffected by oral contraceptives, further supporting the ability of GlyphAgo to bypass first-pass liver metabolism. GlyphAgo demonstrated a 9.6 to 14.5-fold increase in dose-normalized exposure compared to agomelatine in a separate SAD portion of the trial in which no participants were on oral contraceptives.
Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026. This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028. Seaport also expects to initiate a Phase 2b trial of GlyphAgo in the first half of 2027. This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD. Topline data from this trial are expected by the end of 2028. Seaport plans to present additional analyses from the Phase 1 trial at future upcoming scientific meetings.
About GlyphAgo™ (SPT-320 or Glyph Agomelatine)
GlyphAgo is a novel, “Glyphed” oral prodrug of agomelatine, a clinically validated anti-anxiety and antidepressant that is approved for the treatment of GAD in Australia and Major Depressive Disorder in Australia and the European Union. Using Seaport’s proprietary Glyph™ platform, GlyphAgo is designed to enhance lymphatic absorption and avoid first-pass liver metabolism, thereby enhancing oral bioavailability and reducing side effects. By leveraging an alternative absorption pathway via the intestinal lymphatic system used by dietary fats, GlyphAgo is designed to increase systemic exposure of agomelatine, enabling exposure levels of agomelatine that are effective in GAD but at a lower dose that reduces liver exposure and reduces or eliminates the need for liver function testing. Based on the data generated to date, Seaport believes GlyphAgo has the potential to become a leading treatment for GAD.
About Seaport Therapeutics
Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph™ platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding our product candidates, preclinical and clinical development activities and timelines, including projected data announcements, and our expectations for future operations and financial performance. These statements include, among other things, Seaport Therapeutics’ expectations regarding the concurrent Phase 2 trials of GlyphAgo (SPT-320), including the expected trial design and the timing of topline data.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Seaport Therapeutics’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; Seaport Therapeutics’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Seaport Therapeutics’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Seaport Therapeutics’ intellectual property protections; and risks related to the competitive landscape for Seaport Therapeutics’ product candidates; as well as other risks described in “Risk Factors,” in Seaport Therapeutics’ Registration Statement on Form S-1 filed with the Securities and Exchange Commission (SEC), as well as subsequent filings with the SEC. Seaport Therapeutics expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Seaport uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
About PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.
For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to those related to Seaport's development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph™ Platform, the potential of GlyphAgo™ (SPT-320™ or Glyph Agomelatine) and the Glyph platform, the broader applicability of the platform, the addressable market for Seaport's product candidates, if approved, potential benefits to patients, and Seaport's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260608428399/en/
Hyundai Bioscience USA offers Free Drug Supply and Funding for Clinical Trials to WHO Hyundai Bioscience USA offers Free Drug Supply and Funding for Clinical Trials to WHO PR Newswire
SAN JOSE, Calif., June 11, 2026
– Dr. Davey Smith, a Leading U.S. Infectious Disease Expert: "XAFTY® Should Be Urgently Tested to See if it Can Address the Ebola Crisis"
– Lab testing confirms potency against Ebola (IC50) stronger than against COVID-19, trials or emergency use should move quickly given previous human safety data
– Presents an emergency-administration track and regulatory rationale based on the WHO emergency-use guideline of Monitored Emergency Use of Unregistered and Experimental Interventions (MEURI)
, /PRNewswire/ -- Hyundai Bioscience USA announced on June 10 that it has pledged to provide its broad-spectrum antiviral candidate, XAFTY® (CP-COV03), free of charge for emergency use and/or testing for patients in African countries experiencing Ebola outbreaks.
The decision came after Dr. Davey Smith, a virologist and clinical trial expert at University of California San Diego, proposed to Hyundai Bioscience USA the rapid testing of a potential therapeutic and/or prophylactic for Ebola patients in Africa. Agreeing with Dr. Smith's proposal, Hyundai Bioscience USA decided to submit an official letter conveying the proposal to the WHO and to the health authorities of the affected countries.
No-cost clinical supply and rapid testing under emergency provisions based on expert medical judgmentDr. Smith proposed the testing of XAFTY® for Ebola based on his expert judgment that the spread of high-fatality Ebola constitutes a grave emergency, and that XAFTY® meets the conditions for immediate testing under current MEURI rules.
According to the WHO MEURI framework , in a fatal-epidemic emergency for which there is no treatment alternative, a candidate may be administered to patients pre-emptively—even before formal approval, and even if an immediate clinical trial cannot be launched—provided that minimal scientific data (such as cell-based/in vitro results) and clinical safety have been secured.1 2 This is an international public-health mechanism allows the emergency use of unapproved drugs under defined conditions, placing the highest priority on trying to save lives in a crisis.
Dr. Smith considered XAFTY® to fully satisfy these provisions (i.e., in vitro activity and strong human safety profile). Accepting the proposal, Hyundai Bioscience USA plans to respond to the crisis by supplying its stored XAFTY® free of charge and immediately upon request from WHO or local authorities.
Company-Funded Trial Support to Enable Rapid Clinical Evaluation At the same time, the proposal includes a contingency in case the WHO or local health authorities judge that, even amid the crisis, a rapid clinical trial to verify efficacy is more appropriate than immediate emergency administration (MEURI).
Typically, when a country or institution conducts a trial on its own during a public-health crisis, it takes a long time owing to complex procedures and budget-securing issues. Dr. Smith asked Hyundai Bioscience USA whether it would be willing to bear the trial costs directly to shorten this timeline, and the company agreed to deploy a local trial rapidly at its own expense if necessary.
In particular, XAFTY® possesses a firm human drug history that allows it to enter trials immediately in a crisis. Under the guidelines of the International Council for Harmonisation (ICH), a drug whose safety has already been established through large-scale human administration (Phase 2 or higher) may, in a public-health emergency, skip time-consuming animal-efficacy testing and enter clinical trials immediately.3 XAFTY® has already secured human data by successfully completing a 300-person COVID-19 trial in Korea.4 Further, in vitro results showed that the IC50 (the drug concentration that inhibits viral replication by 50%) of XAFTY®'s active ingredient against the Ebola virus produced strong inhibition even at a lower concentration than against SARS-CoV-2, the virus that causes COVID-19.
Jason Kim, President of Hyundai Bioscience USA, said, "In high-fatality diseases such as Ebola, treatment opportunities must not be missed because of procedures and costs." He added, "We decided to provide the drug free of charge and to conduct a company-funded trial to save as many lives as possible. This decision was made because the spread of this highly-fatal virus cannot wait for conventional procedures."
Hyundai Bioscience USA, a member of the U.S. Department of Defense's Medical CBRN Defense Consortium (MCDC), added that the XAFTY® clinical drug it has offered to provide to the affected countries is stored in compliance with regulations and is kept ready for rapid supply once the necessary procedures are completed.
Mr. Kim added, "The very reason a broad-spectrum antiviral exists is to have a therapy readily available when a new virus emerges and threatens lives," and "We hope the WHO and each country's health authorities will reach a rapid and transparent decision by scientifically weighing the therapeutic benefit against the potential risk."
[References]
World Health Organization. Emergency use of unproven clinical interventions outside clinical trials: ethical considerations. Technical document. Geneva: WHO; 25 March 2025. ISBN 9789240041745.World Health Organization. Notes for the record: Consultation on Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) for Ebola Virus Disease (EVD). 17 May 2018.International Council for Harmonisation. M3(R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Current Step 4 version, 11 June 2009. Section 1.3.Kim JH, Kym S, Kim S-W, et al. A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19. Nat Commun. 2025;16:7084. doi:10.1038/s41467-025-62423-4[Appendix] Supporting Materials
[Appendix 1] The Origins of XAFTY® and the Development of a Broad-Spectrum Antiviral
Witnessing civil-society solidarity and launching development: XAFTY®'s development began in the early days of the 2020 COVID-19 pandemic, as the company witnessed the "Clap for Carers" civic movement that spread from London to major cities around the world. Seeing the solidarity between the healthcare workers who cared for patients despite the risk of infection and the citizens who supported them, Hyundai Bioscience took up therapeutic development out of a sense of responsibility that, as a drug-development company, it too should make a tangible technological contribution.Shortening pandemic cycles and defenseless exposure without alternatives: At the time, Hyundai Bioscience analyzed data from the earlier SARS (2003) and MERS (2012) outbreaks and noted the scientific reality that the cycle of new viral epidemics was steadily shortening. Although a pandemic of variant viruses was a foreseeable future, the global pharmaceutical industry had not established in advance a universal treatment platform capable of responding immediately. As a result, in the early days of COVID-19, elderly and frail people isolated in nursing homes and underserved medical areas faced the tragic reality of mass death—left defenseless, with no therapeutic available.A disgrace the pharmaceutical industry must never repeat: Analyzing the large-scale loss of life that occurred in nursing homes, the company engaged in deep self-reflection. It concluded that allowing humanity to be left so defenseless—and to suffer such collective loss—even in the face of an entirely foreseeable shortening of viral cycles was a disgrace and a gap on the part of the pharmaceutical industry as a whole. The conviction that such defenseless sacrifice must never recur became the foundation of XAFTY®'s development.A latecomer's reversal—turning crisis into opportunity: At a time when global pharmaceutical giants such as Pfizer and Merck had moved first to develop therapeutics targeting the specific COVID-19 virus, Hyundai Bioscience was clearly a latecomer. Yet the company turned the disadvantage of late entry into an opportunity. Rather than settling for a drug that treats only the COVID-19 in front of it, it resolved to create a "universal antiviral" capable of addressing even the unknown variant pandemics of the future with a single drug. It treated the pandemic situation—where trial patients were concentrated—as an opportunity to rapidly verify the efficacy of a broad-spectrum drug.The historic precedent of penicillin and a host-cell-targeting mechanism: Just as human average life expectancy was extended by more than 20 years—even without vaccines—after the appearance of penicillin, the first broad-spectrum antibiotic of the 20th century, the company judged that, in the viral-disease domain as well, a universal therapeutic capable of subduing multiple viruses with a single drug is essential. To solve "drug resistance," the chronic limitation of existing targeted therapeutics, it adopted an innovative paradigm that targets the "host-directed pathway" the virus uses to replicate, rather than the virus itself. The philosophy of administering treatment rapidly at the early symptomatic stage—without diagnostic delay for confirmation—to save lives when a new variant emerges: this is the very essence and development story of XAFTY®.[Appendix 2] Dr. Davey Smith's Global Authority in Infectious Diseases and Key Clinical Credentials
Infectious-disease command at a top-tier global research institution: Dr. Davey Smith currently serves as Chief of the Division of Infectious Diseases and Global Public Health at UC San Diego (UCSD). He is a medical authority who has gone beyond basic infectious-disease research to connect real-world clinical practice with public-health policy and to help establish global standards for treating infectious diseases.Lead of the world's largest U.S. government (NIH)-led pandemic trial: During the COVID-19 pandemic, he served as Lead Principal Investigator of the global ACTIV-2 program, into which the U.S. government (NIH) poured an enormous national budget to accelerate therapeutic development worldwide. He rigorously evaluated the candidate therapeutics of numerous global pharmaceutical companies and personally designed and directed multinational trial protocols, gaining experience overseeing global health infrastructure at the front line of pandemic-crisis response.Field experience and clinical control of high-fatality viruses in Africa: He participated as a key investigator in large-scale global clinical trials (such as STOMP) that the U.S. NIH's National Institute of Allergy and Infectious Diseases (NIAID) pursued to address African endemic disease and the global Mpox crisis. Through this, he has gained the most accurate and deep insight into Africa's under-resourced public-health infrastructure, the clinical control of high-risk viruses, and practical cooperation with local health authorities.[Appendix 3] Dr. Davey Smith's Assessment of the Ebola Crisis and the Background to the XAFTY® Proposal
The urgency of Ebola's spread and the necessity of deploying a universal therapeutic: Dr. Smith assessed that the current spread of Ebola in Africa is a grave public-health crisis. In particular, comparing it with Vietnam's dengue outbreak—where flexible regulatory innovation was demonstrated by approving a rapid XAFTY® trial to help overcome the crisis—he judged that, because Ebola's fatality is equal to or greater, the rapid deployment of a "universal antiviral" that can work immediately regardless of variant is essential.Scientific validity based on data for 33 viruses across 16 families: The core basis for Dr. Smith's designation of XAFTY® as an Ebola treatment alternative lies in the broad-spectrum profile of its main active ingredient, niclosamide. According to numerous publications, niclosamide has demonstrated strong in vitro inhibitory activity against 33 major human-infecting viruses representing 16 viral families. This is thanks to a mechanism that modulates the host cell's autophagy pathway, and Ebola, too, can be effectively addressed through this approach.Pre-established human safety and risk–benefit analysis: XAFTY® has already secured human safety data (Human Data)—including the attainment of blood drug concentrations in the body—by completing a 300-subject COVID-19 Phase 2/3 trial in Korea. Vietnam's Ministry of Health likewise approved a dengue trial without animal-efficacy testing on the basis of this scientific data. Dr. Smith analyzed that, rather than the risk of waiting months for animal testing amid a shortage of BSL-4 facilities, the therapeutic benefit obtained by administering a drug already confirmed safe is overwhelmingly greater.[Appendix 4] International Guidelines for Emergency Clinical Trials and Administration, and the Validity of XAFTY®'s Drug History
1. The WHO emergency-use rule (MEURI framework) and emergency validity: The WHO's MEURI guideline is an official provision that permits even an unapproved drug—provided that safety data exist and the scientific basis is clear—to be administered pre-emptively to patients during the spread of an infectious disease for which there is no treatment alternative. Because XAFTY® has secured a firm safety profile, Dr. Smith judged that the current Ebola emergency fully meets these conditions.2. Grounds for company-funded trial entry and omission of animal testing in a crisis (ICH rules): Under the guidelines of the International Council for Harmonisation (ICH), a drug whose safety has already been established through large-scale human administration (Phase 2 or higher) may, in a public-health emergency, skip animal-efficacy testing and immediately enter clinical trials.3. Immediate-trial feasibility based on XAFTY®'s drug history: XAFTY® has already secured COVID-19 human data (Human Data). The U.S. affiliate's offer to bear the full cost and support a rapid trial is a realistic and scientific alternative that uses the fast track permitted under international rules to lawfully save patients.[Appendix 5] Broad-Spectrum Profile and in vitro (Cell-Based) Results of the Active Ingredient Niclosamide
Antiviral activity against 33 viruses across 16 families: Niclosamide, XAFTY®'s main ingredient, showed meaningful antiviral activity at the cellular level against 33 human-infecting viruses belonging to 16 viral families. Because it assists the cell's autophagy mechanism rather than directly attacking a specific virus, it is resilient to variants.Ebola virus IC50 analysis: When the IC50—the concentration required to inhibit by 50% the activity of a virus, cell, enzyme, or the like—was measured, XAFTY®'s IC50 against the Ebola virus was superior (i.e., at a lower concentration) to that against COVID-19, whose efficacy has been proven in human trials, or against dengue virus, currently in trials.Pharmacokinetic (PK) validity: On the basis of the blood drug concentrations in the body confirmed through the trial in 300 COVID-19 patients, the Ebola virus, too, can be expected to show sufficiently effective inhibitory activity within the existing dosing range. View original content to download multimedia:https://www.prnewswire.com/news-releases/hyundai-bioscience-usa-offers-free-drug-supply-and-funding-for-clinical-trials-to-who-302797761.html
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company to watch right now is Park Hotels & Resorts (PK - Free Report) . PK is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock is trading with a P/E ratio of 5.89, which compares to its industry's average of 16.85. Over the past year, PK's Forward P/E has been as high as 7.11 and as low as 4.38, with a median of 5.77.
PK is also sporting a PEG ratio of 1.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. PK's industry has an average PEG of 1.62 right now. PK's PEG has been as high as 6.29 and as low as 0.61, with a median of 1.28, all within the past year.
Another valuation metric that we should highlight is PK's P/B ratio of 0.71. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks attractive against its industry's average P/B of 1.97. PK's P/B has been as high as 0.88 and as low as 0.52, with a median of 0.70, over the past year.
Finally, investors should note that PK has a P/CF ratio of 6.18. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 15.39. Within the past 12 months, PK's P/CF has been as high as 6.25 and as low as 4.43, with a median of 5.21.
Value investors will likely look at more than just these metrics, but the above data helps show that Park Hotels & Resorts is likely undervalued currently. And when considering the strength of its earnings outlook, PK sticks out as one of the market's strongest value stocks.
